Organon & Co. (OGN): R&D Expense
$366.00M
Year ended 2025-12-31
$358.00M
Trailing 12 months to 2026-06-30
-8.1%
3-year compound annual growth
+11.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $366.00M | -22.0% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $469.00M | -11.2% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $528.00M | +12.1% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $471.00M | +38.9% | 2025-11-10, From 2022-01-01 |
| 2021-12-31 | $339.00M | +61.4% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $210.00M | -4.5% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $220.00M | n/a | 2022-03-21, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Organon & Co. (OGN) | 2025-12-31 | $366.00M | -22.0% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $2.15B | +9.9% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $368.00M | +7.0% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $782.74M | -11.5% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $95.40M | -15.0% |
| Zoetis Inc. (ZTS) | 2025-12-31 | $698.00M | +1.7% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $629.00M | +2.1% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $1.32B | +17.2% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $921.93M | +23.4% |
Compare OGN, ONC, ELAN, JAZZ side by side · Screen every company in Pharmaceutical Preparations ↗